Market closedNon-fractional
Protalix BioTherapeutics/PLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Protalix BioTherapeutics
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Ticker
PLX
Sector
Healthcare
Trading on
AMEX
Industry
Biotechnology
Headquarters
Karmiel, Israel
Employees
208
Website
www.protalix.com
PLX Metrics
BasicAdvanced
$77M
Market cap
16.08
P/E ratio
$0.07
EPS
0.90
Beta
-
Dividend rate
Price and volume
Market cap
$77M
Beta
0.9
Financial strength
Current ratio
1.375
Quick ratio
0.953
Long term debt to equity
15.104
Total debt to equity
88.538
Interest coverage (TTM)
2.76%
Management effectiveness
Return on assets (TTM)
6.44%
Return on equity (TTM)
44.48%
Valuation
Price to earnings (TTM)
16.081
Price to revenue (TTM)
1.257
Price to book
2.59
Price to tangible book (TTM)
2.59
Price to free cash flow (TTM)
17.16
Growth
Revenue change (TTM)
45.00%
Earnings per share change (TTM)
-121.27%
3-year revenue growth
4.30%
3-year earnings per share growth
-45.02%
What the Analysts think about PLX
Analyst Ratings
Majority rating from 1 analysts.
PLX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.7M
-64.42%
Net income
-$4.5M
-25.00%
Profit margin
-121.62%
110.82%
PLX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q2 24
Actual
$0.21
-$0.04
-$0.07
-
Expected
-$0.04
-$0.07
-$0.03
$0.02
Surprise
-625.00%
-42.86%
133.33%
-
PLX News
AllArticlesVideos
Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout
PRNewsWire·3 weeks ago
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm
Accesswire·4 weeks ago
Protalix BioTherapeutics to Present at the 2024 BIO International Convention
PRNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Protalix BioTherapeutics stock?
Protalix BioTherapeutics (PLX) has a market cap of $77M as of July 06, 2024.
What is the P/E ratio for Protalix BioTherapeutics stock?
The price to earnings (P/E) ratio for Protalix BioTherapeutics (PLX) stock is 16.08 as of July 06, 2024.
Does Protalix BioTherapeutics stock pay dividends?
No, Protalix BioTherapeutics (PLX) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Protalix BioTherapeutics dividend payment date?
Protalix BioTherapeutics (PLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Protalix BioTherapeutics?
Protalix BioTherapeutics (PLX) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Protalix BioTherapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.